Status:
UNKNOWN
Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency
Lead Sponsor:
University of Saskatchewan
Collaborating Sponsors:
Canadian Blood Services
Conditions:
Plasminogen Deficiency
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
Congenital plasminogen deficiency causes impaired wound healing and growth of pseudomembranous lesions over multiple parts of the body. The most common lesions involve eyes and are known as Ligneous c...
Detailed Description
This study will enroll one patient with recurrent ligneous conjunctivitis at University of Saskatchewan, Saskatchewan Health Authority in Saskatoon. BACKGROUND: Congenital plasminogen deficiency is ...
Eligibility Criteria
Inclusion
- Patients under the age of 18 years
- Diagnosis of plasminogen deficiency (Definition: clinical presence of pseudomembranous lesions and serum plasminogen level \< 50%)
- Ocular involvement (Ligneous Conjunctivitis) due to plasminogen deficiency
Exclusion
- Patient is 18 years or older
- Patients with no plasminogen deficiency
- Patients with no ocular manifestations of plasminogen deficiency
Key Trial Info
Start Date :
December 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05404932
Start Date
December 15 2022
End Date
December 31 2024
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N0W8